{
    "nctId": "NCT00209092",
    "briefTitle": "Randomized Phase II Trial Induction Therapy for Early Stage Breast Cancer",
    "officialTitle": "Randomized Phase II Trial of Sequential Docetaxel Followed by Capecitabine Versus Concomitant, Dose-Dense Docetaxel/Capecitabine as in Induction Therapy for Early Stage Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 51,
    "primaryOutcomeMeasure": "Number of Participants With Complete Pathologic Response Rate to Pre-operative Treatment in Arm A (Docetaxel for 4 Cycles Followed by Capecitabine for 4 Cycles) or Arm B (Docetaxel + Capecitabine for 8 Cycles) in Patients With Early Stage Breast Cancer.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically or cytologically confirmed breast carcinoma.\n* Early stage breast cancer (stage 1, 2, 3).\n* No evidence of disease outside the breast or chest wall, except ipsilateral axillary lymph nodes.\n* 18 years of age or older.\n* Final eligibility for a clinical trial is determined by the health professionals conducting the trial.\n\nExclusion Criteria:\n\n* Prior chemotherapy, hormonal therapy, biologic therapy or radiation therapy for breast cancer.\n* Major surgery within 28 days of study entry.\n* Evidence of central nervous system (CNS) metastases.\n* Final eligibility for a clinical trial is determined by the health professionals conducting the trial.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}